William J. Sandborn - 14 Dec 2022 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
President and Chief Medical Officer
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Issuer symbol
VTYX
Transactions as of
14 Dec 2022
Net transactions value
-$1,424,316
Form type
4
Filing time
16 Dec 2022, 16:00:16 UTC
Previous filing
09 May 2022
Next filing
18 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Options Exercise $8,464 +2,391 +4.9% $3.54* 50,780 14 Dec 2022 Direct
transaction VTYX Common Stock Options Exercise $5,517 +3,189 +6.3% $1.73* 53,969 14 Dec 2022 Direct
transaction VTYX Common Stock Options Exercise $3,236 +16,180 +30% $0.2000* 70,149 14 Dec 2022 Direct
transaction VTYX Common Stock Sale $737,085 -21,760 -31% $33.87 48,389 14 Dec 2022 Direct F1
transaction VTYX Common Stock Options Exercise $4,184 +20,922 +60% $0.2000* 55,799 14 Dec 2022 By Spouse
transaction VTYX Common Stock Sale $708,632 -20,922 -37% $33.87 34,877 14 Dec 2022 By Spouse F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTYX Stock Option (right to buy) Options Exercise $0 -2,391 -100% $0.000000* 0 14 Dec 2022 Common Stock 2,391 $3.54 Direct
transaction VTYX Stock Option (right to buy) Options Exercise $0 -3,189 -100% $0.000000* 0 14 Dec 2022 Common Stock 3,189 $1.73 Direct
transaction VTYX Stock Option (right to buy) Options Exercise $0 -16,180 -33% $0.000000 32,209 14 Dec 2022 Common Stock 16,180 $0.2000 Direct F3
transaction VTYX Stock Option (right to buy) Options Exercise $0 -20,922 -86% $0.000000 3,272 14 Dec 2022 Common Stock 20,922 $0.2000 By Spouse F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average share price of an aggregate total of 21,760 shares sold in the price range of $33.5325 to $34.10. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2 Represents the weighted average share price of an aggregate total of 20,922 shares sold in the price range of $33.5325 to $34.10. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2019 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the total shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 6, 2019.
F4 Subject to the Reporting Person's spouse continuing to be a Service Provider (as defined in the Issuer's 2019 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the total shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 6, 2019.

Remarks:

President and Chief Medical Officer